<p>艾伯维（NYSE:ABBV - 获取免费报告）在周一发布的研究报告中，摩根大通将其目标价从 250.00 美元上调至 260.00 美元，Benzinga 报道。该公司目前对该股票给予 “增持” 评级。摩根大通的目标价意味着该股票当前价格有 20.05% 的潜在上涨空间。</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅超预期第三季度财报后的新底部</li>
</ul>
<p>其他一些股票分析师也最近对该股票进行了评论。Evercore ISI 将艾伯维的目标价从 207.00 美元上调至 222.00 美元，并在 9 月 22 日的研究报告中给予该股票 “跑赢大盘” 评级。华尔街 Zen 在 10 月 25 日的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”。Piper Sandler 在 10 月 10 日的报告中将艾伯维的目标价从 231.00 美元上调至 284.00 美元，并给予该公司 “增持” 评级。Erste Group Bank 在 10 月 14 日的报告中将艾伯维的评级从 “买入” 下调至 “持有”。最后，富国银行在 9 月 12 日的研究报告中将艾伯维的目标价从 240.00 美元上调至 260.00 美元，并给予该股票 “增持” 评级。两位投资分析师对该股票给予强烈买入评级，十六位分析师给予买入评级，九位分析师给予持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 236.35 美元。</p>
<p><strong>查看我们关于艾伯维的最新研究报告</strong></p>
<h2>艾伯维股票表现</h2>
<ul>
<li>为什么艾伯维和强生可能会超越辉瑞</li>
</ul>
<p>NYSE:ABBV 周一开盘价为 216.57 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务股本比率为 44.14。该公司的 50 日简单移动平均为 222.42 美元，200 日简单移动平均为 201.15 美元。该公司的市值为 3825.9 亿美元，市盈率为 103.13，市盈增长比率为 1.42，贝塔值为 0.51。艾伯维的 52 周低点为 163.81 美元，52 周高点为 244.81 美元。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日发布了其财报。该公司报告本季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该公司本季度的收入为 157.8 亿美元，而一致预期为 155.8 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。与去年同期相比，该公司的收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为 3.320-3.360 每股收益。整体来看，股票分析师预计艾伯维在当前财政年度的每股收益为 12.31 美元。</p>
<h2>内部人士下注</h2>
<ul>
<li>3 只卓越股票以建立长期财富</li>
</ul>
<p>在相关消息中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该股票。股份以平均价格 198.42 美元出售，总交易额为 8,407,055.40 美元。出售后，该执行副总裁在公司持有 177,292 股，价值 35,178,278.64 美元。这代表其持股减少了 19.29%。该交易在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。股份以平均价格 198.51 美元出售，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁在公司持有 58,247 股，价值 11,562,611.97 美元。该交易使其持股减少了 18.58%。该销售的 SEC 文件提供了更多信息。目前，0.25% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近调整了对该公司的持股。Conning Inc.在第二季度将其在艾伯维的持股增加了 7.1%。Conning Inc.现在拥有 191,023 股该公司的股票，价值 35,458,000 美元，此前在上个季度增持了 12,690 股。Dohj LLC 在第二季度将其在艾伯维的持股增加了 41.8%。Dohj LLC 现在拥有 4,529 股该公司的股票，价值 802,000 美元，此前在上个季度增持了 1,335 股。第一夏威夷银行在第二季度将其在艾伯维的持股增加了 0.8%。第一夏威夷银行现在拥有 7,556 股该公司的股票，价值 1,403,000 美元，此前增持了 60 股。Narus Financial Partners LLC 在第一季度将其在艾伯维的持股增加了 25.3%。Narus Financial Partners LLC 现在拥有 1,988 股该公司的股票，价值 417,000 美元，此前增持了 401 股。最后，BankPlus 信托部门在第二季度将其在艾伯维的持股增加了 3.3%。BankPlus 信托部门现在拥有 27,113 股该公司的股票，价值 5,033,000 美元，此前增持了 855 股。目前，70.23% 的股票由机构投资者和对冲基金持有。</p>
<h2>艾伯维公司简介</h2>
<p>（获取免费报告）</p>
<p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>何时出售股票以获利或止损</li>
<li>波音在 2018 年以来最佳交付季度中逼近空客</li>
<li>如何购买黄金股票并投资黄金</li>
<li>将其放在我的卡上：奢侈品牌与支付公司为何相得益彰</li>
<li>万亿美元市值的意义超越了数字</li>
<li>适合任何市场的三只安全稳健股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

<p>摩根大通已将艾伯维（NYSE:ABBV）的目标价格从 250.00 美元上调至 260.00 美元，维持 “增持” 评级。这个新目标暗示当前股价有 20.05% 的上涨潜力。其他分析师也调整了对艾伯维的评级和目标价格，平均评级为 “适度买入”，目标价格为 236.35 美元。艾伯维最近公布了强劲的第三季度财报，超出预期，每股收益为 1.86 美元，营收为 157.8 亿美元，同比增长 9.1%</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) had its target price upped by JPMorgan Chase &amp; Co. from $250.00 to $260.00 in a research note issued on Monday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price points to a potential upside of 20.05% from the stock's current price.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）在周一发布的研究报告中，摩根大通将其目标价从 250.00 美元上调至 260.00 美元，Benzinga 报道。该公司目前对该股票给予 “增持” 评级。摩根大通的目标价意味着该股票当前价格有 20.05% 的潜在上涨空间。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅超预期第三季度财报后的新底部</li>
</ul>
</div><p>A number of other equities analysts also recently commented on the stock. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, September 22nd. Wall Street Zen raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, October 25th. Piper Sandler upped their target price on shares of AbbVie from $231.00 to $284.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, October 10th. Erste Group Bank cut shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Finally, Wells Fargo &amp; Company upped their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $236.35.</p>
<div class="lb-trans"><p>其他一些股票分析师也最近对该股票进行了评论。Evercore ISI 将艾伯维的目标价从 207.00 美元上调至 222.00 美元，并在 9 月 22 日的研究报告中给予该股票 “跑赢大盘” 评级。华尔街 Zen 在 10 月 25 日的研究报告中将艾伯维的评级从 “持有” 上调至 “买入”。Piper Sandler 在 10 月 10 日的报告中将艾伯维的目标价从 231.00 美元上调至 284.00 美元，并给予该公司 “增持” 评级。Erste Group Bank 在 10 月 14 日的报告中将艾伯维的评级从 “买入” 下调至 “持有”。最后，富国银行在 9 月 12 日的研究报告中将艾伯维的目标价从 240.00 美元上调至 260.00 美元，并给予该股票 “增持” 评级。两位投资分析师对该股票给予强烈买入评级，十六位分析师给予买入评级，九位分析师给予持有评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 236.35 美元。</p>
</div><p><strong>View Our Latest Research Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我们关于艾伯维的最新研究报告</strong></p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>艾伯维股票表现</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么艾伯维和强生可能会超越辉瑞</li>
</ul>
</div><p>NYSE:ABBV opened at $216.57 on Monday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a fifty day simple moving average of $222.42 and a two-hundred day simple moving average of $201.15. The company has a market cap of $382.59 billion, a price-to-earnings ratio of 103.13, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81.</p>
<div class="lb-trans"><p>NYSE:ABBV 周一开盘价为 216.57 美元。该公司的速动比率为 0.61，流动比率为 0.74，债务股本比率为 44.14。该公司的 50 日简单移动平均为 222.42 美元，200 日简单移动平均为 201.15 美元。该公司的市值为 3825.9 亿美元，市盈率为 103.13，市盈增长比率为 1.42，贝塔值为 0.51。艾伯维的 52 周低点为 163.81 美元，52 周高点为 244.81 美元。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近在 10 月 31 日发布了其财报。该公司报告本季度每股收益为 1.86 美元，超出分析师一致预期的 1.77 美元，超出幅度为 0.09 美元。该公司本季度的收入为 157.8 亿美元，而一致预期为 155.8 亿美元。艾伯维的净利润率为 6.45%，股本回报率为 699.66%。与去年同期相比，该公司的收入增长了 9.1%。在去年同期，该公司每股收益为 3.00 美元。艾伯维已将其 2025 年第四季度的指导目标设定为 3.320-3.360 每股收益。整体来看，股票分析师预计艾伯维在当前财政年度的每股收益为 12.31 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>3 Exceptional Stocks to Build Long-Term Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只卓越股票以建立长期财富</li>
</ul>
</div><p>In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股该股票。股份以平均价格 198.42 美元出售，总交易额为 8,407,055.40 美元。出售后，该执行副总裁在公司持有 177,292 股，价值 35,178,278.64 美元。这代表其持股减少了 19.29%。该交易在与证券交易委员会的法律文件中披露，相关信息可通过此链接获取。此外，执行副总裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股该公司的股票。股份以平均价格 198.51 美元出售，总价值为 2,639,190.45 美元。出售完成后，该执行副总裁在公司持有 58,247 股，价值 11,562,611.97 美元。该交易使其持股减少了 18.58%。该销售的 SEC 文件提供了更多信息。目前，0.25% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the business. Conning Inc. grew its position in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company's stock worth $35,458,000 after acquiring an additional 12,690 shares during the last quarter. Dohj LLC boosted its position in shares of AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company's stock valued at $802,000 after purchasing an additional 1,335 shares in the last quarter. First Hawaiian Bank raised its stake in AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock worth $1,403,000 after buying an additional 60 shares during the period. Narus Financial Partners LLC raised its stake in AbbVie by 25.3% during the 1st quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock worth $417,000 after buying an additional 401 shares during the period. Finally, BankPlus Trust Department raised its stake in AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock worth $5,033,000 after buying an additional 855 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该公司的持股。Conning Inc.在第二季度将其在艾伯维的持股增加了 7.1%。Conning Inc.现在拥有 191,023 股该公司的股票，价值 35,458,000 美元，此前在上个季度增持了 12,690 股。Dohj LLC 在第二季度将其在艾伯维的持股增加了 41.8%。Dohj LLC 现在拥有 4,529 股该公司的股票，价值 802,000 美元，此前在上个季度增持了 1,335 股。第一夏威夷银行在第二季度将其在艾伯维的持股增加了 0.8%。第一夏威夷银行现在拥有 7,556 股该公司的股票，价值 1,403,000 美元，此前增持了 60 股。Narus Financial Partners LLC 在第一季度将其在艾伯维的持股增加了 25.3%。Narus Financial Partners LLC 现在拥有 1,988 股该公司的股票，价值 417,000 美元，此前增持了 401 股。最后，BankPlus 信托部门在第二季度将其在艾伯维的持股增加了 3.3%。BankPlus 信托部门现在拥有 27,113 股该公司的股票，价值 5,033,000 美元，此前增持了 855 股。目前，70.23% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯维公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯维公司在全球范围内发现、开发、生产和销售药品。该公司提供 Humira，一种用于自身免疫性和肠道贝赫切特病及脓皮病的注射剂；Skyrizi 用于治疗中度至重度斑块型银屑病、银屑病性关节炎和克罗恩病；Rinvoq 用于治疗类风湿性关节炎、银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴性脊柱关节炎、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血癌患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Boeing Closes in on Airbus With Best Delivery Quarter Since 2018</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Put It on My Card: Why Luxury Brands and Payments Firms Pair Well</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>3 Safe and Steady Stocks for Any Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过艾伯维</li>
<li>何时出售股票以获利或止损</li>
<li>波音在 2018 年以来最佳交付季度中逼近空客</li>
<li>如何购买黄金股票并投资黄金</li>
<li>将其放在我的卡上：奢侈品牌与支付公司为何相得益彰</li>
<li>万亿美元市值的意义超越了数字</li>
<li>适合任何市场的三只安全稳健股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

艾伯维（NYSE:ABBV）被摩根大通给予新的 260.00 美元目标价